HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

3,4-Diaminopyridine

HCID 5918
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
54-96-6
Standard SMILES
Nc1ccncc1N
InChIKey
OYTKINVCDFNREN-UHFFFAOYSA-N
Molecular formula
C5H7N3
Average molar mass
109.13 g/mol
Monoisotopic mass
109.06399724

Overview

Amifampridine is an aminopyridine.

Names & identifiers

Preferred name
3,4-Diaminopyridine
IUPAC
pyridine-3,4-diamine
English name
3,4-Diaminopyridine
Molecular formula
C5H7N3
Molecular weight
109.13

Names & synonyms

3,4-DIAMINOPYRIDINEpyridine-3,4-diamine54-96-6Amifampridine3,4-Pyridinediamine4,5-Diaminopyridine3,4-DAPPyridine, 3,4-diamino-amifampridinaSC103,4 Diaminopyridineamifampridinum
Show more names
3,4-diamino-pyridinNSC 521760AmipyridineWLN: T6NJ CZ DZTIMTEC-BB SBB004341
DTXSID6046715RU4S6E2G0JNSC-5217605-22-11-00266 (Beilstein Handbook Reference)DTXCID4026715NSC521760RefChem:54154N07XX05

Database identifiers

CAS
54-96-6
PubChem CID
5918
DTXSID
DTXSID6046715
ChEMBL
CHEMBL354077
ChEBI
CHEBI:135948
UNII
RU4S6E2G0J
EC Number
200-220-9
Nikkaji
J51.295H

Properties

Computed structural properties

XLogP
-0.5
Topological polar surface area
64.9 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
3
Rotatable bonds
0
Heavy atoms
8
Formal charge
0
Complexity
74.1

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP-0.5
Solubility · 2 items

freely soluble in water, and slightly soluble in solvents ethanol, methanol and acetic acid

12.2 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 3 items

Breastfeeding; Lactation; Neuromuscular Agents; Potassium Channel Blockers;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

Physicochemical properties

Melting point
216 · 216-218 °C (lit.)
Boiling point
194.6 °C · 194.6°C (rough estimate)
Density
1.1118 · 1.1118 (rough estimate)
refractive index
1.534 · 1.5340 (estimate)
Flash point
240 °C · 240 °C
storage temp.
30 °C · Store below +30°C.

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H300 (94.2%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P261, P262, P264, P264+P265, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P319, P320, P321, P330, P332+P317, P337+P317, P361+P364, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 52 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information3,4-Diaminopyridine: HSNO Approval: HSR004250 Approved with controls
Hazard Classes and CategoriesAcute Tox. 2 (94.2%)

Toxicology

Hepatotoxicity · 1 item

Amifampridine has had limited clinical use, but adverse events have been largely neurologic and gastrointestinal. Serum ALT elevations were not reported in the prelicensure studies of amifampridine but were reported as occurring in a small proportion of patients in safety reviews by the Food and Drug Administration. Nevertheless, there have been no reports of clinically apparent liver injury associated with its use. Thus, liver injury from amifampridine must be rare if it occurs at all.

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Amifampridine

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein BindingIn vitro human plasma protein binding of amifampridine and 3-N-acetyl amifampridine was 25.3% and 43.3%, respectively.
Pharmacodynamics · 1 item

Administration of amifampridine to patients with LES in clinical trials resulted in improvement of the compound muscle action potential (CMAP), muscle function, and quantitative myasthenia gravis (QMG) score. One case of a slight prolongation of the QTc interval in male patient with LEMS and euthyroid Hashimoto’s disease treated with 90 mg of amifampridine in combination with 100 mg azathioprine was reported. _In vitro_, amifampridine was shown to modulate cardiac conduction and induce phasic contractions in different arteries from several species. In addition, it stimulated potassium-evoked dopamine and noradrenaline release in rat hippocampal slices and upregulate acetylcholine release in the brain. It may also potentiate adrenergic and cholinergic neuromuscular transmission in the gatrointestinal tract. In a single pharmacokinetic study, no effect was observed of amifampridine phosphate on cardiac repolarization as assessed using the QTc interval. There were no changes in heart rate, atrioventricular conduction or cardiac depolarization as measured by the heart rate, PR and QRS interval durations.

Mechanism of Action · 1 item

Amifampridine is a symptomatic treatment that increases acetylcholine concentrations at the neuromuscular junction. It selectively blocks presynaptic fast voltage-gated potassium channels, thereby prolonging cell membrane depolarization and action potential, and augmenting calcium transport into the nerve endings. Increased intracellular calcium enhances the exocytosis of acetylcholine-containing vesicles and enhances impulse transmission at central, autonomic, and neuromuscular synapses. Amifampridine improves muscle strength and resting compound muscle action potential (CMAP) amplitudes with an overall weighted mean difference of 1.69 mV.

Biological Half-LifeThe average elimination half-life of amifampridine was 3.6 to 4.2 hours and 4.1 to 4.8 hours for the 3-N-acetyl amifampridine metabolite.

Related reactions

121 records
New reaction record
HRID 20075 reaction equation
HRID 20075As reactant
HRID 62097 reaction equation
HRID 62097As reactant
HRID 82077 reaction equation
HRID 82077As reactant
HRID 82614 reaction equation
HRID 82614As reactant
HRID 193036 reaction equation
HRID 193036As reactant
HRID 257423 reaction equation
HRID 257423As reactant
HRID 266834 reaction equation
HRID 266834As reactant
HRID 274333 reaction equation
HRID 274333As reactant
PreviousPage 1 of 16

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
solubility
30 g/l · 30g/l
form
Crystalline Powder
pka
9.17 · 9.17±0.12(Predicted)
color
Brownish to brown-gray
Water Solubility
24 g/L · 24 g/L (20 ºC)
Merck
14 · 14,2986
BRN
110232 · 110232
InChI
InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
InChIKey
OYTKINVCDFNREN-UHFFFAOYSA-N
SMILES
C1=NC=CC(N)=C1N
CAS DataBase Reference
54 · 54-96-6(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
4 S6E2G0J · RU4S6E2G0J
NCI Drug Dictionary
amifampridine
ATC code
7 XX05 · N07XX05
Comptox DTXSID
6046715 · DTXSID6046715
UNSPSC Code
12352116 · 12352116
NACRES
22 · NA.22
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
300 · H300+H330-H311-H319
Precautionary statements
260 · P260-P264-P280-P302+P352+P312-P304+P340+P310-P305+P351+P338
PPE
3 · Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Hazard Codes
T+,T,Xi
Risk Statements
25 · 25-26-36/37/38
Safety Statements
26 · 26-28-36/37/39-45-37/39-28A-36
RIDADR
2811 · UN 2811 6.1/PG 2
WGK Germany
3 · 3
RTECS
7600000 · US7600000
F
10 · 10-23
Autoignition Temperature
480 °C · 480 °C
Hazard Note
Irritant
HazardClass
6.1 · 6.1
PackingGroup
I
HS Code
2933399090 · 2933399090
Storage Class
6.1 A · 6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
2 InhalationAcute · Acute Tox. 2 InhalationAcute Tox. 2 OralAcute Tox. 3 DermalEye Irrit. 2
Toxicity
50 orally · LD50 orally in Rabbit: 47 mg/kg LD50 dermal Rabbit > 200 mg/kg
Limited Quantities
0.5 Kg · 0.5 Kg (solid)
Excepted Quantities
Max Inner Pack (1g or 1ml) and Max Outer Pack (500g or 500ml)
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation

Safety data

F
10-23
PPE
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
wgk
3
rtecs
US7600000
ridadr
UN 2811 6.1/PG 2
hs_code
2933399090
Toxicity
LD50 orally in Rabbit: 47 mg/kg LD50 dermal Rabbit > 200 mg/kg
risk_code
25-26-36/37/38
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T+,T,Xi
hazard_note
Irritant
safety_code
26-28-36/37/39-45-37/39-28A-36
hazard_class
6.1
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
packing_group
I
Hazard statements
H300+H330-H311-H319
Limited Quantities
0.5 Kg (solid)
Excepted Quantities
Max Inner Pack (1g or 1ml) and Max Outer Pack (500g or 500ml)
Hazard Classifications
Acute Tox. 2 InhalationAcute Tox. 2 OralAcute Tox. 3 DermalEye Irrit. 2
Autoignition Temperature
480 °C
Precautionary statements
P260-P264-P280-P302+P352+P312-P304+P340+P310-P305+P351+P338
Metabolism/MetabolitesAmifampridine is extensively metabolized by N-acetyltransferase 2 (NAT2) to 3-N-acetyl-amifampridine, which is considered an inactive metabolite.
FDA Pharmacological Classification · 5 items

RU4S6E2G0J

AMIFAMPRIDINE

Established Pharmacologic Class [EPC] - Potassium Channel Blocker

Mechanisms of Action [MoA] - Potassium Channel Antagonists

Amifampridine is a Potassium Channel Blocker. The mechanism of action of amifampridine is as a Potassium Channel Antagonist.

MeSH Pharmacological Classification · 2 items

Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS.

Absorption, Distribution and Excretion · 4 items

Orally-administered amifampridine is rapidly absorbed in humans to reach the peak plasma concentrations within by 0.6 to 1.3 hours. A single oral dose of 20 mg amifampridine in fasted individuals resulted in mean peak plasma concentrations (Cmax) ranging from 16 to 137 ng/mL. Bioavailability is approximately 93-100% based on recoveries of unmetabolised amifampridine and a major 3-N-acetylated amifampridine metabolite in urine. Food consumption decreases amifampridine absorption and exposure with a decrease in the time to reach maximum concentrations (Tmax). It is approximated that food consumption lowers the Cmax on average by ~44% and lowers AUC by ~20%. based on geometric mean ratios. Systemic exposure to amifampridine is affected by the overall metabolic acetylation activity of NAT enzymes and NAT2 genotype. The NAT enzymes are highly polymorphic that results in variable slow acetylator (SA) and rapid acetylator (RA) phenotypes. Slow acetylators are more prone to increased systemic exposure to amifampridine, and may require higher doses for therapeutic efficacy.

Following oral administration, more than 93% of total amifampridine is renally eliminated within 24 hours. About 19% of the total renally-excreted dose is in the parent drug form, and about 74-81.7% of the dose is in its metabolite form.

In healthy volunteers, the volume of distribution for plasma amifampridine indicated that RUZURGI is a drug with a moderate to a high volume of distribution. After a 2 mg/kg infusion in rats, the volume of distribution at steady-state was 2.8 ± 0.7 L/kg. Drug concentrations were highest in organs of excretion, including the liver, kidney, and the gastrointestinal tract, and some tissues of glandular function, such as lacrimal, salivary, mucous, pituitary, and thyroid glands. Concentrations in tissues are generally similar to or greater than concentrations in plasma.

Overall clearance of amifampridine is both metabolic and renal; it is primarily cleared from the plasma via metabolism by N-acetylation. Following oral administration of a single 20 or 30 mg dose of RUZURGI to healthy volunteers, amifampridine apparent oral clearance (CL/F) was 149 to 214 L/h.

Applications · 3 items

Description3,4-diaminopyridine (3,4-DAP, amifampridine) is the leading treatment for Lambert–Eaton myasthenic syndrome (LEMS), an autoimmune disorder with impaired neuromuscular transmission, for which few effective medications are currently available. 3,4-DAP has been available as a therapy for LEMS in special treatment programmes for approximately 25 years.

UsesAmifampridine (3,4-Diaminopyridine) is a drug, predominantly in the treatment of a number of rare muscle diseases. 3,4-Diaminopyridine (3,4-DAP) is used in the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and some congenital myasthenic syndromes (CMS). It is used to improve muscle strength.

UsesIt is a potassium channel blocker in nerve terminals. It inhibits potassium channel efflux, increasing the duration of the action potential, which results in an increase in the duration of calcium channel opening and enhanced acetylcholine (ACh) release. Increased ACh availability at the motor end plate allows muscles to contract.

Upstream & downstream products

Upstream raw materials

Fuming sulfuric acidAmmonium hydroxidePalladium4-Hydroxypyridine4-Amino-3-nitropyridinePhosphorus pentachlorideNitric acidMethanolAmmonium acetateActivated carbon

Downstream products

5-Azabenzimidazole4-Chloro-1-H-imidazo[4,5-c]pyridineAMifaMpridine Phosphate

Additional notes

DefinitionChEBI: Amifampridine is an aminopyridine.